ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer

Pfizer and Astellas’ Xtandi is already approved to treat nonmetastatic castration-resistant prostate cancer, thanks to data showing it can stop tumors from spreading. But now it’s adding results that show it can help patients live longer, too.